Log In Sign up
The largest database of trusted experimental protocols

The RL (GCB-DLBCL) is a cell line derived from a patient with diffuse large B-cell lymphoma (DLBCL) of the germinal center B-cell (GCB) subtype. It is a widely used model for studying this type of lymphoma.

Automatically generated - may contain errors

Lab products found in correlation

Penicillin, by Thermo Fisher Scientific (2 mentions) Streptomycin, by Thermo Fisher Scientific (2 mentions) Rpmi 1640, by Thermo Fisher Scientific (2 mentions) Hepes, by Thermo Fisher Scientific (2 mentions) Fetal bovine serum (fbs), by Atlanta Biologicals (2 mentions) U2932 abc dlbcl, by American Type Culture Collection (2 mentions) Karpas 422, by Leibniz Institute DSMZ (2 mentions) Nu dhl 1, by Leibniz Institute DSMZ (1 mentions) Su dhl 4, by Leibniz Institute DSMZ (1 mentions) Sudhl6, by Leibniz Institute DSMZ (1 mentions) Oci ly19, by Leibniz Institute DSMZ (1 mentions)

2 protocols using rl gcb dlbcl

1

Establishment and Characterization of DLBCL Cell Lines

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
RL (GCB-DLBCL) and U2932 (ABC-DLBCL) cell lines were obtained from American Type Culture Collection (Rockville, MD). Rituximab-resistant cell lines (RL 4RH and U2932 4RH) were created as described previously (Czuczman et al. 2008 (link)). Other cell lines representing ABC-DLBCL (TMD8, HBL-1) and GCB-DLBCL (SUDHL-4, SUDHL-6, SUDHL-10, OCI-LY2, OCI-LY19, BJAB, HT, DB, Karpas-422, NUDHL-1) were obtained from Leibniz Institute/German Collection of Microorganisms and Cell Cultures (DSMZ). All cell lines were maintained in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA), 5mM HEPES, 100U/mL penicillin and 100μg/mL streptomycin (Life Technologies, Grand Island, NY) at 37oC and 5%CO2.
Neoplastic B-cells were isolated from pre-treatment biopsy tissue (either lymph node or extranodal tumor tissue) obtained from patients with B-cell NHL or Hodgkin lymphoma (HL) receiving therapy at Roswell Park Comprehensive Cancer Center (RPCCC) as previously described (Brem et al. 2011 (link)).
Torka P., Mavis C., Kothari S., Belliotti S., Gu J., Sundaram S., Barth M, & Hernandez‐Ilizaliturri F.J. (2020). Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. EJHaem, 1(1), 122-132.
+ Open protocol
+ Expand
2

Establishing Rituximab-Resistant DLBCL Cell Lines

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
RL (GCB‐DLBCL) and U2932 (ABC‐DLBCL) cell lines were obtained from American Type Culture Collection (Rockville, MD). Rituximab‐resistant cell lines (RL 4RH and U2932 4RH) were created as described previously [17 (link)]. Other cell lines representing ABC‐DLBCL (TMD8, HBL‐1) and GCB‐DLBCL (SUDHL‐4, SUDHL‐6, SUDHL‐10, OCI‐LY2, OCI‐LY19, BJAB, HT, DB, Karpas‐422, NUDHL‐1) were obtained from Leibniz Institute/German Collection of Microorganisms and Cell Cultures (DSMZ). All cell lines were maintained in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% heat‐inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA), 5 mM HEPES, 100 U/mL penicillin, and 100 µg/mL streptomycin (Life Technologies, Grand Island, NY) at 37°C and 5% CO2.
Neoplastic B‐cells were isolated from pre‐treatment biopsy tissue (either lymph node or extranodal tumor tissue) obtained from patients with B‐cell NHL or Hodgkin lymphoma (HL) receiving therapy at Roswell Park Comprehensive Cancer Center (RPCCC) as previously described [18 (link)].
Torka P., Mavis C., Kothari S., Belliotti S., Gu J., Sundaram S., Barth M, & Hernandez‐Ilizaliturri F.J. (2020). Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. EJHaem, 1(1), 122-132.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!